ARCHIVES

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

This article is from The Cancer Letter archive.

Vol. 40 No. 06 | February 7, 2014

Download PDF Visit The Full Archive

Related Articles

Lenalidomide, An Altered Thalidomide, Shows Promise

November 24, 2006

Dana-Farber Picks Rosenthal To Direct New Center For Integrated Therapies.

June 23, 2000

In Brief: Gori to Return As Head Of Smoking Program; Wisconsin, AACI To Honor Harold Rusch

May 18, 1979

The Varmus Era: Controversy Continues

January 6, 1995

RPR Grant To NABCO Does Not Support Advocacy, Firm Says

November 10, 1995

NCI Director and Acting FDA Commissioner Andrew von Eschenbach Endorses Rep. E. Clay Shaw In Tour of Florida Congressman’s District. Von Eschenbach Praises Shaw’s “Leadership” In Seeking Funding For Research, Support of 2015 Goal.

February 3, 2006